[Form 4] Invizyne Technologies Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 highlights: Exozymes Inc. (ticker EXOZ) filed a Form 4 disclosing that Chief Executive Officer Michael Heltzen received a new equity award on 06/17/2025.

• Security granted: Non-qualified stock options covering 235,817 shares of common stock.
• Exercise price: $12.40 per share.
• Vesting schedule: Options vest quarterly over four years, beginning 07/01/2025, and fully vest by mid-2029.
• Expiration: 06/29/2032.
• Post-grant holdings: 235,817 derivative securities beneficially owned (no direct share ownership reported, no shares sold).

The filing indicates a routine compensation grant rather than an open-market purchase or sale. While it does not immediately alter cash flow or earnings, it increases potential future share count and reinforces long-term alignment between the CEO and shareholders. No other transactions, amendments, or 10b5-1 plans were disclosed.

Positive

• Long-term, performance-linked incentives align the CEO’s financial outcome with shareholder value creation.
• No insider selling accompanies the grant, avoiding negative market signal.

Negative

• Potential dilution of up to 235,817 additional shares if options are exercised.

Insights

Financial Analyst

TL;DR: Routine CEO option grant; minimal dilution risk; neutral immediate impact.

The award equals 235,817 options at $12.40, roughly the cost basis management must exceed for value creation. With an eight-year term and four-year vesting, incentive duration is long, matching typical growth-stage biotech practices. The absolute share count’s dilution effect cannot be quantified without shares outstanding, but on its own it is unlikely to be material. No insider selling was recorded, avoiding negative sentiment. Overall, the filing is procedural rather than market-moving.

Corporate Governance Expert

TL;DR: Governance-standard equity compensation; aligns CEO with investors; dilution modest.

Quarterly vesting discourages short-termism, and the 07/01/2025 start date imposes a six-week cliff, incentivising performance continuity. Absence of a 10b5-1 reference implies discretionary timing, but given it is an initial grant to a newly listed company (implied by lack of prior holdings) the risk is low. From a governance perspective, granting options instead of restricted stock shifts value risk to the executive, which shareholders generally prefer. The filing is neutral to mildly positive for governance ratings.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Heltzen Michael

(Last) (First) (Middle)

C/O 750 ROYAL OAKS DRIVE, SUITE 106

(Street)

MONROVIA CA 91016

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EXOZYMES INC. [ EXOZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options for Common Stock(1)	$12.4	06/17/2025		A		235,817		06/17/2025	06/29/2032	Common Stock	235,817	$0	235,817	D

Explanation of Responses:

1. The Options will vest over a four (4) year period, in equal quarterly installments at the end of each quarter of the calendar year, and the Options will commence vesting on July 1, 2025.The option expires June 29, 2032.

	/s/ Michael Heltzen	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Exozymes (EXOZ) disclose in the latest Form 4?

EXOZ reported a grant of 235,817 stock options to CEO Michael Heltzen at a $12.40 exercise price.

When do the newly granted EXOZ options vest?

They vest quarterly over four years, beginning 07/01/2025 and ending in 2029.

What is the expiration date of the CEO’s options?

All unexercised options expire on 06/29/2032.

Did the CEO buy or sell any EXOZ common shares?

No. The filing only reports an option grant; no common shares were purchased or sold.

How many derivative securities does the CEO own after the transaction?

He beneficially owns 235,817 derivative securities (options).

Is this filing considered material to EXOZ investors?

It is largely administrative; the grant adds possible dilution but has no immediate financial impact.